Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma.
- Author:
Xiang-dong HUA
1
;
Zhong-ye HE
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; therapeutic use; Carboplatin; administration & dosage; Carcinoma, Hepatocellular; drug therapy; surgery; therapy; Catheter Ablation; methods; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; administration & dosage; Female; Fluorouracil; administration & dosage; Follow-Up Studies; Humans; Iodized Oil; administration & dosage; Liver Neoplasms; drug therapy; surgery; therapy; Male; Microwaves; therapeutic use; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; analogs & derivatives; therapeutic use; Phenylurea Compounds; therapeutic use; Protein Kinase Inhibitors; therapeutic use; Remission Induction; Survival Rate
- From: Chinese Journal of Oncology 2012;34(10):790-792
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer.
METHODSFrom January 2006 to January 2010, 90 patients with recurrent hepatocellular carcinoma (HCC) were treated with MCT and TACE in our hospital. The treatment group received sorafenib + MCT + TACE, and the control group received MCT + TACE.
RESULTSRR of the treatment group was 66.7%, which of the control group was 52.0% (P > 0.05). DCR was 83.3% in the treatment group and 64.5% in the control group (P < 0.05). Through a comparison of survival curves along with the extension of time, the survival rates of the two groups were decreased, but the treatment group (group 1) had a significantly higher one than the control group (group 2), with a statistically significant difference (P < 0.05).
CONCLUSIONSorafenib combined with MCT and TACE can improve the disease control rate and prolong the survival in patients with recurrent HCC.
